NZ193890A - 3,5-diamino-6-(substituted phenyl)-1,2,4-triazines and pharmaceutical compositions - Google Patents

3,5-diamino-6-(substituted phenyl)-1,2,4-triazines and pharmaceutical compositions

Info

Publication number
NZ193890A
NZ193890A NZ193890A NZ19389080A NZ193890A NZ 193890 A NZ193890 A NZ 193890A NZ 193890 A NZ193890 A NZ 193890A NZ 19389080 A NZ19389080 A NZ 19389080A NZ 193890 A NZ193890 A NZ 193890A
Authority
NZ
New Zealand
Prior art keywords
hydrogen
group
formula
iii
compound
Prior art date
Application number
NZ193890A
Other languages
English (en)
Inventor
M G Baxter
A R Elphick
A A Miller
D A Sawyer
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ193890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to NZ19815980A priority Critical patent/NZ198159A/en
Publication of NZ193890A publication Critical patent/NZ193890A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ193890A 1979-06-01 1980-05-30 3,5-diamino-6-(substituted phenyl)-1,2,4-triazines and pharmaceutical compositions NZ193890A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ19815980A NZ198159A (en) 1979-06-01 1980-05-30 Guanidine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01

Publications (1)

Publication Number Publication Date
NZ193890A true NZ193890A (en) 1984-07-06

Family

ID=10505597

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ193890A NZ193890A (en) 1979-06-01 1980-05-30 3,5-diamino-6-(substituted phenyl)-1,2,4-triazines and pharmaceutical compositions

Country Status (30)

Country Link
US (2) US4486354A (cg-RX-API-DMAC7.html)
EP (2) EP0021121B1 (cg-RX-API-DMAC7.html)
JP (2) JPS5625169A (cg-RX-API-DMAC7.html)
AR (1) AR227521A1 (cg-RX-API-DMAC7.html)
AT (1) AT370097B (cg-RX-API-DMAC7.html)
AU (2) AU530999B2 (cg-RX-API-DMAC7.html)
BG (1) BG60427B2 (cg-RX-API-DMAC7.html)
CA (1) CA1112643A (cg-RX-API-DMAC7.html)
CS (1) CS234018B2 (cg-RX-API-DMAC7.html)
CZ (1) CZ384891A3 (cg-RX-API-DMAC7.html)
DD (1) DD151309A5 (cg-RX-API-DMAC7.html)
DK (1) DK153787C (cg-RX-API-DMAC7.html)
ES (1) ES491998A0 (cg-RX-API-DMAC7.html)
FI (1) FI67844C (cg-RX-API-DMAC7.html)
GE (1) GEP19960470B (cg-RX-API-DMAC7.html)
GR (1) GR68380B (cg-RX-API-DMAC7.html)
HU (1) HU182086B (cg-RX-API-DMAC7.html)
IE (1) IE49823B1 (cg-RX-API-DMAC7.html)
IL (1) IL60201A (cg-RX-API-DMAC7.html)
IT (1) IT1147087B (cg-RX-API-DMAC7.html)
MX (1) MX9202962A (cg-RX-API-DMAC7.html)
MY (1) MY8500062A (cg-RX-API-DMAC7.html)
NL (1) NL950007I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ193890A (cg-RX-API-DMAC7.html)
PL (1) PL124029B1 (cg-RX-API-DMAC7.html)
SU (1) SU1055331A3 (cg-RX-API-DMAC7.html)
UA (1) UA5576A1 (cg-RX-API-DMAC7.html)
YU (1) YU145680A (cg-RX-API-DMAC7.html)
ZA (1) ZA803250B (cg-RX-API-DMAC7.html)
ZW (1) ZW12980A1 (cg-RX-API-DMAC7.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0024351B1 (en) * 1979-08-16 1984-10-31 The Wellcome Foundation Limited Solid pharmaceutical formulation containing substitued phenyl-triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
CZ286723B6 (cs) * 1991-01-30 2000-06-14 The Wellcome Foundation Limited Tablety dispergovatelné ve vodě
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
IL105986A (en) * 1992-06-12 1998-12-06 Wellcome Found Pharmaceutical preparations containing triazine compounds for the prevention or reduction of tolerable dependence or the opposite of dependency
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
ATE219487T1 (de) * 1994-12-30 2002-07-15 Wellcome Found Verfahren zur herstellung von lamotrigine
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
WO2000035888A1 (en) * 1998-12-14 2000-06-22 Sharad Kumar Vyas An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
IN183150B (cg-RX-API-DMAC7.html) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
JP2002541215A (ja) * 1999-04-09 2002-12-03 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬組成物およびその使用
US6639072B1 (en) 2000-01-03 2003-10-28 Rpg Life Sciences Limited Process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
PL365378A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
PT1337271E (pt) 2000-11-30 2005-01-31 Pfizer Prod Inc Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase
EP1390355A4 (en) * 2001-02-27 2005-02-23 Teva Pharma NEW CRYSTALLINE FORMS OF LAMOTRIGIN AND METHOD FOR THE PRODUCTION THEREOF
ATE317280T1 (de) 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
WO2003090693A2 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
AU2003217437A1 (en) * 2003-03-17 2004-10-11 Hetero Drugs Limited Novel crystalline forms of lamotrigine
US7504516B2 (en) 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
DK1809271T5 (da) * 2004-09-10 2010-12-06 Newron Pharm Spa Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
DK1931335T3 (da) * 2005-09-23 2010-06-07 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatorer
JP2009508953A (ja) * 2005-09-23 2009-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロ−シクロヘプタピラゾール系カンナビノイドモジュレーター
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
KR20080050511A (ko) 2005-09-23 2008-06-05 얀센 파마슈티카 엔.브이. 테트라하이드로-사이클로펜틸 피라졸 카나비노이드모듈레이터
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
EP2024345B1 (en) * 2006-05-31 2009-12-16 Calaire Chimie SAS Method for preparing lamotrigine and its intermediate 2,3-dichlorobenzoyl chloride
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
CN101506178A (zh) * 2006-08-14 2009-08-12 隆沙有限公司 制备拉莫三嗪的方法
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) * 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CA2760219C (en) 2009-05-13 2016-08-16 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
EP2564836A1 (en) 2009-05-20 2013-03-06 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
US10189859B2 (en) * 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
TWI808952B (zh) 2016-12-16 2023-07-21 瑞士商愛杜西亞製藥有限公司 包含t型鈣通道阻斷劑之醫藥組合
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
GB2641294A (en) 2024-05-24 2025-11-26 Novumgen Ltd An orodispersible tablet of Lamotrigine and its process of preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (cg-RX-API-DMAC7.html) * 1964-05-05
DE1802364C3 (de) * 1967-10-12 1975-03-20 Shell Internationale Research Maatschappij B.V., Den Haag (Niederlande) Arzneimittel mit thymeretischer Wirkung
GB1223492A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
EP0024351B1 (en) * 1979-08-16 1984-10-31 The Wellcome Foundation Limited Solid pharmaceutical formulation containing substitued phenyl-triazines

Also Published As

Publication number Publication date
IT1147087B (it) 1986-11-19
ZA803250B (en) 1982-01-27
EP0059987A1 (en) 1982-09-15
FI67844C (fi) 1985-06-10
JPS6133163A (ja) 1986-02-17
IE801126L (en) 1980-12-01
IL60201A0 (en) 1980-07-31
ES8104993A1 (es) 1981-05-16
AU5890680A (en) 1980-12-04
IT8048848A0 (it) 1980-05-30
JPH0144179B2 (cg-RX-API-DMAC7.html) 1989-09-26
CZ384891A3 (en) 1993-10-13
EP0059987B1 (en) 1985-08-14
PL224633A1 (cg-RX-API-DMAC7.html) 1981-02-13
BG60427B2 (bg) 1995-03-31
ES491998A0 (es) 1981-05-16
GEP19960470B (en) 1996-08-29
SU1055331A3 (ru) 1983-11-15
CS234018B2 (en) 1985-03-14
JPH0144706B2 (cg-RX-API-DMAC7.html) 1989-09-29
YU145680A (en) 1983-02-28
US4486354A (en) 1984-12-04
ATA289680A (de) 1982-07-15
NL950007I1 (nl) 1995-06-16
NL950007I2 (nl) 1997-02-03
DK233880A (da) 1980-12-02
UA5576A1 (uk) 1994-12-28
AU530999B2 (en) 1983-08-04
DD151309A5 (de) 1981-10-14
EP0021121B1 (en) 1983-05-11
DK153787C (da) 1989-01-16
ZW12980A1 (en) 1982-01-06
MX9202962A (es) 1992-07-01
AT370097B (de) 1983-02-25
FI801758A7 (fi) 1980-12-02
MY8500062A (en) 1985-12-31
FI67844B (fi) 1985-02-28
DK153787B (da) 1988-09-05
HU182086B (en) 1983-12-28
AR227521A1 (es) 1982-11-15
US4602017A (en) 1986-07-22
IL60201A (en) 1984-05-31
EP0021121A1 (en) 1981-01-07
PL124029B1 (en) 1982-12-31
JPS5625169A (en) 1981-03-10
IE49823B1 (en) 1985-12-25
CA1112643A (en) 1981-11-17
GR68380B (cg-RX-API-DMAC7.html) 1981-12-28
AU566870B2 (en) 1987-11-05

Similar Documents

Publication Publication Date Title
NZ193890A (en) 3,5-diamino-6-(substituted phenyl)-1,2,4-triazines and pharmaceutical compositions
CA1261328A (en) Triazine compounds having cardiovascular activity
KR910002254B1 (ko) 트리아진 염의 제조방법
SK178598A3 (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
JPH0316344B2 (cg-RX-API-DMAC7.html)
HU209576B (en) Process for producing pyrimidine derivatives and pharmaceutical preparations containing them
EP0021120B1 (en) 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
WO1987002584A1 (en) Cis-n-(2-aminocycloaliphatic)benzene acetamide and -benzamide anticonvulsants
JP4248245B2 (ja) ６−フェニルベンゾナフチリジン
HUT60726A (en) Process for producing 3,5-diamino-6-(4-aminochlorophenyl)-1,2,4-triazine derivatives acting on central nervous system, and pharmaceutical compositions comprising such compounds
JPH0153266B2 (cg-RX-API-DMAC7.html)
JPH0141616B2 (cg-RX-API-DMAC7.html)
CA1133938A (en) Substituted aromatic compounds
US4311701A (en) Treatment of convulsions with triazines
US5095018A (en) 3-benzyl-1,2,4-triazolo[4,3-α] pyrazines
PL182361B1 (pl) Pochodne 6-metoksy-1H-benzotriazolo-5-karboksyamidu, sposoby ich wytwarzaniai kompozycje farmaceutyczne zawierajace te pochodne PL PL PL PL PL PL PL PL
JP2000500455A (ja) 血液調節化合物
JP2000500463A (ja) 血液調節化合物
JPH01301683A (ja) 新規セフエム化合物